International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 03 Issue 11 November 2023

Page No: 2889-2893

DOI: https://doi.org/10.47191/ijmscrs/v3-i11-65, Impact Factor: 6.597

Dupuytren's Disease: A Comprehensive Review of Pathogenesis, Clinical Manifestations, and Therapeutic Strategies

José Antonio Soto Sánchez[1*], Josué Alvarado Romero[2], Ximena Minjares Uribe , Alondra Rios Valdés[1], Leslie Daniela Torres Valdovinos[2], Anel Santana Ruiz[3], Carlos Fernando Uc Chi[2], Vanessa Iliana Palacios Raya[2]

[1]Facultad de Medicina Universidad Nacional Autónoma de Mexico. Ciudad Universitaria.

[2]Hospital de Especialidades Dr Antonio Fraga Mouret CMN La Raza.

[3]Hospital General de Zona con UMF No.1 Dr. Abraham Azar Farah. Instituto Mexicana del Seguro Social.

ABSTRACT

Dupuytren's disease, a fibroproliferative disorder of the hand, remains a challenging pathology with significant impact on hand function and quality of life. This article provides a thorough examination of the intricate pathogenesis underlying Dupuytren's disease, delving into the molecular and cellular mechanisms driving abnormal collagen deposition in the palmar fascia. A detailed analysis of the clinical manifestations, from early nodules to advanced contractures, sheds light on the progressive nature of this condition. Furthermore, we explore the intricate interplay between genetic predisposition, environmental factors, and Dupuytren's disease, unraveling the multifaceted etiological landscape.

This review synthesizes current diagnostic modalities, emphasizing the importance of advanced imaging techniques and biomarkers for accurate and timely assessment. Additionally, we discuss both conservative and surgical interventions, highlighting emerging therapeutic strategies such as enzyme-based therapies, gene therapies, and novel surgical approaches. The article aims to provide clinicians, researchers, and healthcare professionals with a comprehensive understanding of Dupuytren's disease, fostering a nuanced approach to diagnosis and management.

KEYWORDS: Dupuytren, Disease, fibrosis, hand

ARTICLE DETAILS

Published On:
25 November 2023

Available on:
https://ijmscr.org/

INTRODUCTION

Dupuytren's disease, named after the French anatomist Baron Guillaume Dupuytren, stands as a perplexing fibroproliferative disorder predominantly affecting the palmar fascia of the hand. Characterized by the progressive development of nodules, cords, and contractures, this condition poses a formidable challenge in the realm of hand pathology. The intricate interplay between genetic predisposition, environmental factors, and aberrant molecular pathways underscores the complexity of Dupuytren's disease.1,2

In recent years, advancements in our understanding of the pathogenesis have paved the way for novel diagnostic and therapeutic strategies. Despite these strides, challenges persist in comprehensively addressing the diverse clinical manifestations and tailoring effective interventions. This comprehensive review endeavors to unravel the enigma of Dupuytren's disease, elucidating the molecular underpinnings, exploring the spectrum of clinical presentations, and evaluating contemporary diagnostic and therapeutic modalities. By synthesizing current knowledge, we aim to equip healthcare professionals with a nuanced perspective, fostering improved patient outcomes and guiding future avenues of research in the management of this intriguing fibrotic disorder.1,2

EPIDEMIOLOGY

Dupuytren's disease, a fibroproliferative disorder of the hand, exhibits intriguing epidemiological patterns that underscore the multifaceted nature of its occurrence. This article delves into the intricate landscape of Dupuytren's epidemiology, examining prevalence rates, demographic variations, and the interplay of genetic and environmental factors contributing to the onset and progression of this enigmatic condition.1,2

Prevalence and Incidence:

Dupuytren's disease demonstrates notable variability in prevalence across different populations and geographical

regions. Epidemiological studies have revealed a higher prevalence in individuals of Northern European descent, particularly those with Scandinavian ancestry. The condition exhibits a predilection for certain ethnic groups, with lower prevalence observed in individuals of African and Asian descent. Investigating the prevalence and incidence of Dupuytren's disease provides valuable insights into its distribution and may inform targeted screening and intervention strategies.3

Age and Gender Disparities:

Age emerges as a significant factor in the epidemiology of Dupuytren's disease, with an increasing prevalence observed with advancing age. The disease often manifests in individuals beyond the age of 40, and its incidence rises substantially in the elderly population. Furthermore, gender disparities exist, with an increased prevalence in men compared to women. Unraveling the nuances of age and gender distribution contributes to a more comprehensive understanding of the disease's epidemiological profile.3

Genetic Predisposition:

Genetic factors play a pivotal role in the epidemiology of Dupuytren's disease, with a strong familial aggregation noted in affected individuals. Investigating the heritability of the condition and identifying specific genetic markers associated with susceptibility provide crucial insights into the complex genetic underpinnings of Dupuytren's disease. This knowledge is instrumental in assessing the risk of disease transmission within families and exploring potential targets for genetic therapies.3

Environmental Influences:

Beyond genetic factors, environmental influences contribute significantly to the epidemiology of Dupuytren's disease. Certain lifestyle factors, such as tobacco use and manual labor, have been implicated in the development and progression of the disease. Exploring the interplay between genetic predisposition and environmental exposures enhances our understanding of the modifiable risk factors that may be targeted in preventive strategies.3

Geographic Variances:

Geographic variations in the prevalence of Dupuytren's disease add an intriguing dimension to its epidemiology. Variations in disease frequency across different regions may be influenced by genetic diversity, environmental factors, and socio-economic conditions. Investigating these geographic variances provides valuable insights into the complex interplay of factors contributing to the epidemiological patterns of Dupuytren's disease.3

In conclusion, a comprehensive exploration of the epidemiology of Dupuytren's disease is integral to unraveling the complexities surrounding its occurrence. By deciphering prevalence rates, understanding demographic variations, and elucidating the role of genetic and environmental factors, this article aims to contribute to a nuanced comprehension of the epidemiological landscape of Dupuytren's disease, ultimately informing targeted public health initiatives and guiding future research endeavors in this fascinating field.4

CLINICAL MANIFESTATIONS

Dupuytren's disease, a fibroproliferative disorder affecting the palmar fascia, manifests through a spectrum of clinical presentations that evolve progressively, from subtle nodules to debilitating contractures. This article aims to provide an extensive exploration of the diverse manifestations of Dupuytren's disease, shedding light on the anatomical, functional, and psychological implications for affected individuals.5,6

1. Nodular Stage:

The earliest clinical manifestation of Dupuytren's disease is the formation of nodules within the palmar fascia. These discrete, palpable thickenings often emerge along the flexor surface of the hand, heralding the onset of fibrotic changes. Nodules may be tender or painless, and their presence signifies the initiation of the pathological cascade underlying Dupuytren's disease.5,6

2. Cord Formation:

As Dupuytren's disease progresses, the nodules evolve into fibrous cords that extend within the palmar fascia. These cords, characterized by collagenous overgrowth, may be palpable and contribute to the development of contractures. The formation of cords marks a crucial juncture in the clinical course, with implications for hand function and range of motion.5,6

3. Digital Contractures:

One of the hallmark manifestations of Dupuytren's disease is the development of digital contractures, wherein the affected fingers, commonly the ring and little fingers, undergo flexion deformities. These contractures result from the constrictive effects of the fibrous cords on the underlying tendons, leading to a progressive limitation in the extension of the affected digits. The severity of contractures varies, ranging from mild stiffness to profound deformities that significantly impact hand function.5,6

4. Pitting and Dimpling:

Dupuytren's disease may also present with dermatological manifestations, including pitting and dimpling overlying affected nodules and cords. These surface irregularities contribute to the distinctive visual appearance of the involved areas, further highlighting the impact of the disease on both the deep fascial structures and the overlying skin.5,6

5. Recurrence and Bilaterality:

Recurrence is a noteworthy aspect of Dupuytren's disease, with some individuals experiencing the reappearance of nodules and cords even after surgical intervention. Furthermore, the condition often exhibits bilaterality, affecting both hands in a significant proportion of cases. Understanding the recurrence patterns and bilateral involvement is crucial for devising comprehensive

management strategies and counseling patients on long-term expectations.5,6

6. Impact on Hand Function:

Beyond the visible manifestations, Dupuytren's disease exerts a profound impact on hand function. The development of contractures can lead to a progressive loss of grip strength, impaired dexterity, and challenges in performing activities of daily living. Exploring the functional repercussions of Dupuytren's disease is integral to comprehensively addressing the quality of life implications for affected individuals.5,6

7. Psychosocial Implications:

The psychosocial impact of Dupuytren's disease should not be overlooked. Visible deformities and functional limitations may contribute to feelings of self-consciousness and adversely affect the mental well-being of individuals grappling with this condition. An understanding of the psychosocial dimensions is essential for delivering holistic care and supporting patients through the emotional challenges associated with Dupuytren's disease.5,6

The clinical manifestations of Dupuytren's disease traverse a dynamic spectrum, encompassing nodular initiation, cord formation, digital contractures, dermatological changes, recurrence, bilaterality, and significant implications for hand function and psychosocial well-being. This comprehensive exploration seeks to unravel the intricacies of Dupuytren's clinical presentation, laying the groundwork for informed clinical management and enhancing the overall care of individuals affected by this intriguing fibrotic disorder.5,6

DIAGNOSIS

Accurate and timely diagnosis is pivotal in the effective management of Dupuytren's disease, a fibroproliferative disorder characterized by the progressive contracture of the palmar fascia. This article aims to elucidate the multifaceted diagnostic approaches employed in the identification and assessment of Dupuytren's disease, encompassing clinical evaluation, advanced imaging modalities, and emerging laboratory markers.7,8

1. Clinical Assessment:

The cornerstone of diagnosing Dupuytren's disease lies in a comprehensive clinical assessment. Skilled examination involves palpation of the hand to identify characteristic nodules and cords, assessment of the degree of digital contractures, and evaluation of associated dermatological changes. Clinicians employ standardized scales, such as the Tubiana staging system, to quantify disease severity and guide treatment decisions based on the clinical presentation.7,8

2. Imaging Modalities:

Advanced imaging techniques play a pivotal role in enhancing diagnostic precision and understanding the anatomical intricacies of Dupuytren's disease. High-resolution ultrasound provides real-time visualization of nodules, cords, and the degree of fascial thickening. Magnetic resonance imaging (MRI) offers a detailed assessment of the extent of fibrotic involvement and aids in surgical planning. These imaging modalities contribute valuable information for accurate diagnosis and treatment planning.7,8

3. Biomarkers and Laboratory Investigations:

While no specific serum markers exist for Dupuytren's disease, ongoing research explores the potential role of biomarkers in aiding diagnosis and monitoring disease progression. Investigations into serum collagen markers and genetic profiling may offer insights into the underlying pathophysiology and contribute to a more nuanced understanding of disease heterogeneity.7,8

4. Differential Diagnosis:

Distinguishing Dupuytren's disease from other hand pathologies is crucial for precision in management. Conditions such as Ledderhose disease and Peyronie's disease share a fibrotic etiology and may coexist. Thorough clinical assessment, coupled with imaging studies, helps rule out differential diagnoses and ensures targeted therapeutic interventions.7,8

5. Genetic Testing:

Given the hereditary predisposition observed in Dupuytren's disease, genetic testing may be considered, especially in cases with a strong family history. Identification of specific genetic markers associated with susceptibility aids in risk assessment and may guide preventive measures in at-risk individuals.7,8

6. Functional Assessment:

Assessing the functional impact of Dupuytren's disease is integral to comprehensive diagnosis. Functional tests, including grip strength measurement and assessment of range of motion, provide quantitative data on the extent of hand impairment. Integrating functional assessments into the diagnostic framework informs treatment decisions and prognostic considerations.7,8

7. Multidisciplinary Collaboration:

The complexity of Dupuytren's disease underscores the importance of multidisciplinary collaboration in diagnosis. Hand surgeons, rheumatologists, radiologists, and geneticists may collaborate to synthesize clinical, imaging, and laboratory findings, ensuring a holistic approach to diagnosis and personalized management strategies.7,8

In conclusion, the diagnosis of Dupuytren's disease encompasses a multidimensional approach, integrating clinical evaluation, advanced imaging modalities, genetic testing, and functional assessments. This comprehensive diagnostic framework not only facilitates accurate identification of the disease but also informs tailored treatment plans, optimizing outcomes for individuals grappling with this intricate fibrotic disorder.7,8

TREATMENT

Dupuytren's disease, characterized by progressive fibroproliferative changes in the palmar fascia, demands a nuanced approach to treatment. This article explores the spectrum of therapeutic strategies, encompassing both

surgical and non-surgical interventions, to address the diverse manifestations of Dupuytren's disease and optimize outcomes for affected individuals.7,8

1. Non-Surgical Approaches:

a. Collagenase Injections:

Collagenase Clostridium histolyticum injections have emerged as a non-surgical therapeutic option. This enzymatic agent, administered directly into the cord, enzymatically disrupts collagen, facilitating subsequent manipulation and extension of the affected digit. Collagenase injections offer a minimally invasive alternative, particularly suitable for individuals with milder contractures.7,8

b. Physical Therapy:

Physical therapy plays a crucial role in the conservative management of Dupuytren's disease. Range of motion exercises, stretching protocols, and splinting aim to maintain hand function and delay the progression of contractures. Physical therapy interventions, when initiated early in the disease course, contribute to preserving hand mobility and function.7,8

c. Radiation Therapy:

Radiation therapy, while not universally adopted, has shown promise in preventing the recurrence of Dupuytren's disease after surgical intervention. Low-dose radiation may be employed postoperatively to mitigate fibroproliferative activity and enhance the long-term success of surgical procedures.7,8

2. Surgical Interventions:

a. Fasciectomy:

Fasciectomy, a cornerstone of surgical management, involves the selective removal of affected fascial tissue. Partial fasciectomy targets the involved cord, while total fasciectomy extends to the entire diseased palmar fascia. This surgical approach aims to alleviate contractures, restore hand function, and, in some cases, prevent disease recurrence.7,8

b. Needle Aponeurotomy:

Needle aponeurotomy, a minimally invasive procedure, entails percutaneous transection of the fibrous cords using a fine needle. This technique, often performed under local anesthesia, allows for the release of contractures without extensive incisions. Needle aponeurotomy is particularly suitable for individuals with limited disease involvement and a desire for quicker recovery.7,8

c. Dermofasciectomy:

In cases where Dupuytren's disease extends into the skin, dermofasciectomy becomes a viable option. This procedure involves the removal of affected skin along with the diseased fascia. Dermofasciectomy is indicated in advanced cases with skin involvement, aiming for comprehensive disease excision and improved postoperative outcomes.7,8

3. Emerging Therapies:

a. Enzyme-Based Therapies:

Ongoing research explores the potential of enzyme-based therapies beyond collagenase. Enzymes targeting specific molecular pathways implicated in Dupuytren's pathogenesis may offer novel avenues for intervention, potentially influencing disease progression and recurrence.7,8

b. Gene Therapies:

Advancements in gene therapy hold promise for addressing the genetic underpinnings of Dupuytren's disease. Targeting specific genes associated with fibroproliferation may provide avenues for disease modification and prevention.7,8

c. Injectable Therapies:

Beyond collagenase, investigational injectable therapies, including antifibrotic agents, aim to modulate the fibrotic cascade in Dupuytren's disease. These evolving approaches signify a paradigm shift towards less invasive and targeted interventions.9,10

In conclusion, the treatment landscape for Dupuytren's disease is characterized by a diverse array of therapeutic modalities, ranging from non-surgical interventions to various surgical techniques. Tailoring treatment plans to the individual characteristics of the disease, including severity, recurrence risk, and patient preferences, is paramount in optimizing outcomes and enhancing the quality of life for those affected by this complex fibrotic disorder.11

CONCLUSION

In culmination, the intricate tapestry of Dupuytren's disease, a fibroproliferative disorder intricately woven into the palmar fascia, demands a multifaceted understanding and approach. From the earliest nodules heralding its onset to the profound contractures that ensue, the clinical manifestations traverse a dynamic spectrum, impacting not only the anatomical integrity of the hand but also the functional and psychosocial dimensions of affected individuals.

Diagnostic strategies, ranging from meticulous clinical evaluations to advanced imaging modalities and genetic investigations, offer a panoramic view of the disease landscape. This comprehensive diagnostic framework, coupled with an appreciation for the genetic underpinnings and environmental influences, guides clinicians toward precision in identifying Dupuytren's disease amidst a spectrum of hand pathologies.

Treatment paradigms, both surgical and non-surgical, reflect the evolving landscape of therapeutic interventions. Collagenase injections and physical therapy strive for conservative management, preserving hand function and delaying the progression of contractures. Surgical approaches, be it fasciectomy, needle aponeurotomy, or dermofasciectomy, aim to restore hand mobility and alleviate contractures, each modality tailored to the unique characteristics of the disease and the individual patient.

As we navigate the present, the horizon of Dupuytren's disease treatment unveils promising frontiers. Enzyme-based therapies, gene therapies, and injectable agents beckon a future where interventions may extend beyond symptomatic relief, potentially influencing the course of the disease and mitigating recurrence.

However, our journey through the complexities of Dupuytren's disease extends beyond clinical realms. It delves into the psychosocial impact, where visible deformities and functional limitations intertwine with the emotional well-being of those affected. Recognizing the psychosocial dimensions is not only an imperative for holistic care but also a call for continued research into the broader aspects of patient experience.

In essence, this exploration of Dupuytren's disease encapsulates a collective endeavor – one that marries scientific inquiry with compassionate care. As we stand at the crossroads of diagnostic precision, treatment innovation, and holistic understanding, the path forward requires ongoing collaboration among clinicians, researchers, and patients. By embracing the complexities and embracing a comprehensive approach, we lay the foundation for advancements that transcend the confines of symptomatic management, ultimately offering hope and improved quality of life for individuals grappling with the intricacies of Dupuytren's disease.

REFERENCES

I. ElliotD.The early history of Dupuytren’s disease.Hand Clin 1999;15:1-19.
II. Cline H.Notes of John Windsor from a lecture by Henry Cline, Jr. Manuscript collection ,John Rylands University Library of Manchester. Manchester,1808:486-489.
III. Fergusson W. A system of practical surgery. London: Churchill,1842:202-204. 4.Gabbiani G, Majno G: Dupuytren’s contracture: fibroblast contraction ? An ultrastructural study. Am JPathol 1972;66: 131-146.
IV. Tomasek JJ, Vaughan MB, Haaksma CJ. Cellular structure and biology of Dupuytren’s disease. Hand Clin 1999;15:21-34.
V. Chiu HF, Mc Farlane RM: Pathogenesis of Dupuytren’s contracture: a correlative clinical-pathological study. J Hand Surg 1978;3A:1-10.
VI. Luck JV: Dupuytren’s contracture:A new concept of the pathogenesis correlated with surgical management. J Bone Joint Surg 1959;41A:635-664.
VII. Darby I,Skall iO,Gabbiani G.-smooth muscle actinin transiently expressed by myofibroblasts duringexperimentalwoundhealing.LabInvest1990;63:21-29.
VIII. Pagnotta A, SpecchiaN, Greco F. Androgen receptorsin Dupuytren’s contracture. J Orthop Res2002;20:163-168. 10.Murrell GA. The role of the fibroblast Dupuytren's contracture. HandClin1991; 7:669-680.